Bras J Rheumatol 2010;50(2):165-75 peptides, 75% human and 25% murine, and it is the agent most commonly associated with acute infusion reactions. 1, 7, 12 Etanercept is a soluble recombinant TNFα receptor composed by a dimeric fusion protein containing a human IgG1 constant region and variable regions of the murine antibody. 2 Similar to infliximab, adalimumab is a monoclonal antibody that causes direct blockade of TNFα, but differ from that agent since it is fully humanized. 4 Local reactions are among the most common side effects in patients treated with subcutaneous anti-TNFα antagonists (etanercept and adalimumab), 4, 5, 14 but, usually, they do not represent a contraindication to continue the treatment. On the other hand, acute reactions can be severe and, although subcutaneous agents are prescribed for in-home administration, side effects are not restricted to intravenous drugs. Anaphylaxis and angioedema have been reported with both administration routes, reinforcing the need of patient supervision. 11, [15] [16] [17] Acute reactions could be explained both by immunologic mechanisms (IgE-mediated), such as urticaria, bronchospasm, hypotension, and tachycardia, and non-allergic mechanisms, resulting in non-specific reactions, such as rubor, diaphoresis, chills, nausea, headache, and chest pain. [7] [8] [9] [10] [11] [12] [13] Usually, signs and symptoms associated with immediate reactions improve by reducing the rate of administration, in the case of infliximab, and treatment with acetaminophen and antihistamines. Severe cases require the use of corticosteroids, NS, and even adrenaline.
The objective of the present study was to evaluate the prevalence and severity of immediate adverse reactions in a large number of intravenous and subcutaneous administrations of those drugs in a university reference center. 
PatIENtS aND mEtHODS

Patients undergoing anti-TNFα therapy
Routine administration of anti-TNFα drugs
All drugs evaluated were administered at the CEDMAC with supervision for both intravenous (infliximab) and subcutaneous (adalimumab and etanercept) drugs. All patients were evaluated, by a nurse or physician, before every administration, to screen for infections and adverse events.
The following intervals, recommended by the manufactures for the administration of the drugs, were followed: infliximab (at 0, 2, 6 weeks and after every 8 th week), adalimumab (every 2 weeks), and etanercept (weekly). For infliximab, patients were pre-treated with intravenous anti-histamines (50 mg of diphenhydramine), followed by the intravenous infusion of the drug over 2 hours, for doses of up to 350 mg, or 3 hours, for higher doses, always diluting the medication in 250 mL of NS; this was followed by a 1-hour observation period.
Adalimumab and etanercept were administered subcutaneously, followed by a 1-hour observation period, after the first dose, or 30 minutes, after posterior doses, monitored continuously to detect adverse reactions.
Immediate complications secondary to the administrations
All signs and symptoms observed by the nursing staff and/or physician, or reported by patients, were considered immediate complications. They were classified as mild (headache, rash, dizziness, pruritus, nausea), moderate (fever, urticaria, palpitation, chest pain, dyspnea, hypotension or hypertension with variation in systolic blood pressure between 20 and 40 mmHg), or severe (high fever with chills, dyspnea with wheezing, hypotension or hypertension with variation in systolic blood pressure > 40 mmHg), according to the literature. 24 
Statistical analysis
Results are presented in numbers (%). Fisher exact test was used to compare the percentage of immediate adverse reactions for all three anti-TNFα drugs. P < 0.05 was considered statistically significant.
rESuLtS
Among 242 patients evaluated, 94 (39%) had a diagnosis of RA, 64 (26%) AS, 31 (13%) PA, 26 (11%) JIA, and 27 3%) , affecting 39/242 (16%) patients. The administration of the anti-TNFα agent was discontinued and/or changed in 7/39 (18%) patients with acute reactions. Among those, 5/10 (50%) were patients with severe reactions, and 2/21 (9.5%) were patients with moderate reactions. Patients with adverse reactions were treated immediately at the dispensation center and, whenever necessary, they were transferred to HC-FMUSP emergency room. Ten reactions (22%), usually related to infliximab (8 patients), but also with adalimumab (1 patient), and etanercept (1 patient), were considered severe ( Table 2 ). Fifty percent of those reactions resulted in discontinuation of the drug.
Nature of the complications
Severe adverse reactions related to adalimumab, etanercept, and infliximab were seen in 1/5 (20%), 1/4 (25%), and 8/36 (22%), respectively, of the total number of complications for each drug.
Complications according to the drug and disease
Immediate complications were seen in 30 (3.7%) patients, with infliximab, 5 (0.5%) with adalimumab, and 4 (0.25%) with etanercept. Immediate complications were more common during infusions of infliximab than during the administration of adalimumab (P < 0.0001) and etanercept (P < 0.0001).
Regarding infliximab, complications were more common during the first hour of infusion (76% of the events) and in the initial phase of the treatment (50% up to the 5 th administration, and 6% in the first infusion). However, reactions were observed up to the 29 th infusion during the follow-up period. Among subcutaneous administrations, 3/9 (33.3%) were observed in the first administration, one after the administration of adalimumab and two after etanercept. The remaining six reactions developed from three months up to one year of treatment.
The distribution of complications according to the diagnosis demonstrated that the rate is similar among the different diseases investigated (P > 0. 
DISCuSSION
The present study showed that, although immediate reactions are rare, they are potentially severe, indicating that their administration should be monitored in centers capable of managing medical emergencies.
The advantage of the present study was the use of a standardized protocol for the systematic evaluation of immediate adverse events, which also includes subcutaneous anti-TNFα drugs. Therefore, due to the development, although rare, of severe immediate reactions, the current recommendation of non-supervised administration of subcutaneous agents at home could be rediscussed. The uniformity of the administration protocol for each of the drugs, therefore validating the development of those events, is another important aspect of this study. The use of prophylactic premedication like corticosteroids or anti-histamines has been related with a reduction in the incidence of acute reactions. 25 The findings of the present study are similar to those reported in recent studies that show 8.6% to 23% [8] [9] [10] 24, 26 prevalence of immediate reactions in RA patients, and 13.2%, 8 in AS patients, during the infusion of infliximab. In the majority of the cases, complications occur between the 4 th and 6 th administration of the drug, 10, 24 which was also observed in the present study. On the other hand, the incidence of those events in JIA observed in the present study, i.e., 12%, is much lower than the 43% reported by a multicenter Brazilian study with children and adolescents with rheumatic diseases (especially JIA) who were treated with infliximab. 26 The route of administration seems to be the most important factor to explain this discrepancy, since all JIA patients in our study were treated with etanercept.
Most immediate reactions were moderate, requiring medical intervention; as for mild reactions, similarly to other reports in the literature, we observed that headache and rash are the most common symptoms. 10, 26 Interruption of the drug administration in moderate events was much lower than that of severe events. Comparison with the literature was hindered due to the non-standardized classification of those events in previous studies. 8, 25 Most of the reactions observed could be classified as immune-mediated, since they developed after the first administration, after previous antigen exposure.
Adverse events were much more common with intravenous infusions, with a similar frequency to that of prior studies, especially in groups premedicated with anti-histamines. 27 They do not seem to be related to the disease because the distribution was similar in the different diseases and it is similar to prior studies. 27, 28, 29 Systemic reactions to anti-TNFα drugs administered subcutaneously are rarely described, being restricted to case reports, such as angioedema of the face, 17 and retrospective analysis of medical records. 29 The prospective, standardized design of supervised administration of the present study is associated with more reliable identification of those reactions that, although rare, they do occur and are potentially severe. Those findings suggest the need of medical supervision during the administration.
To conclude, immediate reactions to anti-TNFα drugs are rare and potentially severe. They develop, predominantly, in the initial injections, both with subcutaneous and intravenous drugs. Thus, immediate reactions to the administration of those biological agents should be the focus of future studies to assess, more precisely, the need to recommend that subcutaneous agents should also be administered in reference centers capable of handling emergencies. 
